Pharmaceuticals

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

The biotech firm faces a delisting threat after its equity turned negative. Can recent funding save its Nasdaq spot and its ambitious drug pipeline?

Pimicotinib, a once-daily pill for tenosynovial giant cell tumor, gains FDA review, offering new hope for patients beyond invasive surgery.

Juvena Therapeutics lands a $33.5M Series B and a major pharma deal to advance its AI-discovered regenerative drugs for neuromuscular diseases.

Private equity firm Five Arrows makes a majority investment in Blue Mountain to fuel AI innovation, product growth, and European expansion for its compliance software.

LyfeSci's acquisition of Clinically Media aims to fix the clinical trial bottleneck by integrating patient recruitment, promising faster, more diverse studies.

As employers pull back coverage for pricey weight-loss drugs, a new partnership offers a flexible way to provide access without breaking the budget.

Austrian firm AOP Health secures nationwide access for its rapid heart rate drug, Rapiblyk™, by partnering with top US distributors. What does this mean for critical care?

Following a successful three-year transformation, B-FLEXION acquires full ownership of Radius Health, betting big on its blockbuster osteoporosis drug TYMLOS®.

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

With FDA alignment for its rapid postpartum depression therapy and new trials for anxiety, Reunion Neuroscience is pioneering a new era of mental health.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

Princeton-based EDETEK will present its AI-powered clinical trial ecosystem at the J.P. Morgan conference, aiming to capture a slice of a booming market.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Recent findings of bacteria and heavy metals in baby formula have parents worried and legal experts demanding greater manufacturer accountability.

With booming revenue, a potential blockbuster on the horizon, and key partnerships, Ascendis Pharma lays out a bold roadmap for global dominance.